Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Clin Lymphoma Myeloma ; 8(3): 153-8, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18650178

ABSTRACT

BACKGROUND: Recent experience with thalidomide maintenance after high-dose chemotherapy with autologous stem cell support has demonstrated improvement in progression-free survival (PFS) and overall survival (OS). We further explored the tolerability and efficacy of lower doses of maintenance thalidomide in this single-institution study. PATIENTS AND METHODS: Thirty-eight patients with myeloma were enrolled and treated with melphalan 200 mg/m(2) followed by autologous stem cell transplantation. Thalidomide 50 mg per day was started on day > or = 60 after recovery of blood counts and was escalated to a maximum dose of 200 mg per day. Responses were assessed at 2 months, 1 year, and 2 years after transplantation. RESULTS: Of the 38 enrolled patients, 7 patients never received thalidomide. Among 31 patients receiving thalidomide, complete or very good partial responses were observed in 65% and 42% of patients at 1 and 2 years, respectively. Tolerability was a major issue, with only 17 patients completing 1 year of thalidomide. The goal of dosing 200 mg per day was achieved in just 17 of 31 patients, and the median tolerated thalidomide dose was 100 mg per day. Sensory neuropathy was the primary reason for dose modification and discontinuation. No thromboembolic events were observed. The median PFS was 20.8 months, and the median OS was > 60 months. CONCLUSION: Thalidomide maintenance at a goal dose of 200 mg per day was not feasible in this population, with our data suggesting that 100 mg per day is a more reasonable maintenance dose.


Subject(s)
Immunosuppressive Agents/administration & dosage , Melphalan/administration & dosage , Multiple Myeloma/mortality , Multiple Myeloma/therapy , Myeloablative Agonists/administration & dosage , Thalidomide/administration & dosage , Adolescent , Adult , Aged , Disease-Free Survival , Female , Follow-Up Studies , Humans , Male , Middle Aged , Stem Cell Transplantation , Survival Rate , Transplantation, Autologous
2.
Clin Infect Dis ; 40(7): e63-6, 2005 Apr 01.
Article in English | MEDLINE | ID: mdl-15824977

ABSTRACT

We describe a case of cow-transmitted parapoxvirus infection--also known as milkers' nodules--after a hematopoietic stem cell transplantation for multiple myeloma. The infection was complicated by erythema multiforme and acute exacerbation of graft-versus-host disease. Parapoxvirus was confirmed by electron microscopy. The natural history of milker's nodules in immunocompetent hosts is described and compared to that in our immunocompromised patient.


Subject(s)
Erythema Multiforme/complications , Graft vs Host Disease/complications , Hematopoietic Stem Cell Transplantation/adverse effects , Multiple Myeloma/therapy , Poxviridae Infections/complications , Adult , Graft vs Host Disease/drug therapy , Humans , Immunosuppressive Agents/therapeutic use , Male , Poxviridae Infections/pathology
3.
Leuk Lymphoma ; 46(10): 1441-8, 2005 Oct.
Article in English | MEDLINE | ID: mdl-16194889

ABSTRACT

We recently described a novel thiotepa plus etoposide high-dose therapy (HDT) conditioning regimen for aggressive histology non-Hodgkin's lymphoma (NHL) that had low regimen-related toxicity (RRT) and an efficacy rate comparable to other NHL HDT regimens. In this report, we describe the UW experience with the addition of total body irradiation (TBI) and pre-transplant involved-field radiation (IFRT) to the thiotepa + etoposide HDT regimen. Between 1992 and 1999, 28 patients with indolent or mantle cell lymphoma were treated on this protocol. With a median follow-up of 64 mo, the median event-free survival (EFS) was 24 months, and the median overall survival (OS) had not been reached. The median number of grade 3 - 4 non-hematologic toxicities was five. There were five deaths (18%) in the first three months after HDT due to RRT. In contrast, the thiotepa + etoposide conditioning regimen (without TBI or IFRT) given to 65 intermediate grade NHL patients resulted in only one treatment-related death and considerably fewer grade 3 - 4 toxicities. Given the relatively short EFS in this cohort of indolent NHL patients, we conclude that the combination of IFRT and TBI plus thiotepa and etoposide resulted in a HDT regimen with excessive toxicity and this protocol was closed at our institution.


Subject(s)
Etoposide/adverse effects , Hematopoietic Stem Cell Transplantation , Lymphoma, Follicular/drug therapy , Lymphoma, Follicular/radiotherapy , Lymphoma, Mantle-Cell/drug therapy , Lymphoma, Mantle-Cell/radiotherapy , Thiotepa/adverse effects , Adult , Aged , Combined Modality Therapy/adverse effects , Etoposide/administration & dosage , Etoposide/therapeutic use , Female , Follow-Up Studies , Humans , Lymphoma, Follicular/surgery , Lymphoma, Mantle-Cell/surgery , Male , Middle Aged , Survival Rate , Thiotepa/administration & dosage , Thiotepa/therapeutic use , Time Factors , Transplantation, Autologous
4.
J Perinat Educ ; 24(3): 188-200, 2015.
Article in English | MEDLINE | ID: mdl-26834440

ABSTRACT

It is important that expectant parents receive accurate information about the benefits and risks of circumcision as well as the benefits and risks of having an intact foreskin when making a decision about routine infant circumcision (RIC). A pilot study was conducted using the shared decision making (SDM) conceptual model to guide expectant parents through a 3-phase decision-making program about RIC as part of their childbirth education class. The participants showed a high level of preparedness following each of the 3 phases. Preparedness score were highest for those who decided to keep their expected sons' penises natural. This SDM program was an effective way of guiding expectant parents through the decision-making process for RIC.

SELECTION OF CITATIONS
SEARCH DETAIL